drugset / Trial / NCT05701774
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.
Timeline
- Start
- 2023-01-31
- Primary completion
- 2028-06
- Completion
- 2028-06
Outcome
Met primary endpoint
release “C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). The study met its primary endpoint” soleno.life ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diazoxide Choline | Unknown | 75 mg | Oral |
| Subject | Diazoxide Choline | Unknown | 525 mg | Oral |